Published by

British Journal of Contemporary Research

BEXFORD PUBLISHING

Tuberculosis in the Diabetic Patient: A Diagnostic Dilemma

Review Article | Volume 1 | Issue 2 | 2026 | Article Number: 044

Accepted: 03 July 2026 | Published: 10 July 2026 | ISSN: 2979-8582 (Online)

Dr. Onuoha-Ojeamiren Gloria Olomiekido[1], Dr. Onuoha Augunus Chidubem[2], Iduda Ojeamiren[3], Ajay kumar P[4], Samuel Olowo Sunday[1]

[1]Department of Medical Microbiology, Faculty of Basic Clinical Science, Ambrose Alli University, Ekpoma , Nigeria,
[2]Department of Chemical Pathology, Faculty of Basic clinical Sciences, Ambrose Alli University Ekpoma, Nigeria,
[3]Department of Laboratory Sciences, Dartford and Gravesham NHS Trust, Kent,
[4]Department of Laboratory Medicine, Central Hospital, South Western Railway, Hubli, Karnataka, India,

DOGO 0000-0003-2236-6014, **DOAC** 0009-0005-6632-3149

Correspondence: Dr. Onuoha-Ojeamiren Gloria Olomiekido, gloriaonoha2@gmail.com

Abstract

Tuberculosis (TB) and diabetes mellitus (DM) overlapping burden is now a growing clinical problem , complicating both early diagnosis and effective treatment. Diabetes increases the risk of TB disease and may worsen clinical outcomes, making early recognition essential. [1,2,3] Because symptoms may be atypical and standard tests may be less straightforward in some patients; a high index of suspicion and integrated screening are important. [4,5]

Keywords: Tuberculosis, Diabetes Mellitus, Diagnostic Dilemma, Screening, Glycemic Control, Comorbidity

Introduction

Tuberculosis continues to account for significant illness and death globally, while the prevalence of diabetes is rising rapidly, especially in low- and middle-income countries where the TB burden is also high. [3, 5] The coexistence of both diseases is clinically important because diabetes is a recognized risk factor for TB and can complicate presentation, diagnosis, and recovery.[2,6]

WHO developed a collaborative framework for TB and diabetes because management requires coordinated action at both the clinical and programmatic levels.[3,4] This framework emphasizes collaboration, detection and management of TB in people with diabetes, and detection and management of diabetes in people with TB.[3,4]

Epidemiology

The burden of TB-diabetes comorbidity is rising because both conditions are increasingly prevalent in the same populations.[2,5] Recent evidence shows that diabetes is associated with a higher risk of active TB disease.[2,6,7] A 2021 systematic review and meta-analysis found a substantial burden of diabetes among TB patients and showed worse outcomes in the TB-diabetes group.[1,2,5]

This overlap is especially concerning in settings with limited diagnostic capacity and high TB transmission, because missed TB in diabetic patients may allow ongoing spread.[3,5] The growing diabetes burden may therefore threaten TB control gains if integrated screening is not consistently implemented.[0,1,3,5]

Pathophysiology

Diabetes impairs host immunity by affecting macrophage function, cytokine signaling, and cellular immune responses needed to contain *Mycobacterium tuberculosis*.[5,6] Hyperglycemia and insulin resistance can further weaken the immune response and may contribute to more severe disease.[6, 7]

The relationship is reciprocal. Active TB can worsen glucose control through inflammation, stress responses, nutritional compromise, and treatment-related effects.[6, 8] Therefore, the clinician must manage TB and diabetes as interdependent conditions rather than separate problems.[3, 4]

Diagnostic dilemma

The central diagnostic problem is that TB in diabetic patients may present in an atypical or attenuated manner.[6,8] Common symptoms associated with TB such as cough, fever, night sweats, fatigue, and cachexia are non-specific and may be attributed to diabetes or another chronic condition.[5,6] Radiographic findings may also be less classic, and bacteriologic confirmation may be delayed or initially negative.[6,8]

Diabetes-related immune dysfunction may also reduce the performance of some TB diagnostic tests, contributing to underdiagnosis and delayed treatment.[4,5] This is especially relevant for TB infection testing, early disease, and extrapulmonary forms where clinical suspicion is critical.[4,9] The key practical point is that TB should remain on the differential diagnosis in any diabetic patient with persistent respiratory or constitutional symptoms.[5,6]

Clinical presentation

Diabetic patients with TB may present with prolonged cough, unexplained weight loss, low-grade fever, reduced appetite, hemoptysis, or constitutional symptoms that do not resolve with routine care. [5,8] in some cases, chest imaging may show cavitary disease or infiltrates, but in others the pattern may not be obvious. [7,8] suboptimal glycaemic control is often associated with severe illness and slower recovery.[1,7]

Latent TB infection should also be considered in selected high-risk diabetic patients, especially in settings with high TB prevalence.[4,9] This does not mean every patient with diabetes needs the same workup, but the threshold for considering TB infection should be lower when epidemiologic risk is high.[3,4]

Diagnostic approach

A structured diagnostic approach is essential. In a diabetic patient with chronic cough, fever, night sweats, weight loss, hemoptysis, or unexplained radiographic findings, TB testing should be initiated promptly. [5, 6] Diagnostic workup should include sputum microscopy, culture, and molecular testing when available.[5,6]

If initial evaluation is negative but suspicion remains high, repeat testing or additional investigations should be pursued rather than stopping the workup.[5,6] In high-risk diabetic patients, clinicians may also consider testing for TB with tuberculin skin test or interferon-gamma release assays when appropriate.[4,9] The diagnostic strategy should be adapted to local resources, but it should never be passive or delayed.[3,4]

Screening and integration

Bidirectional screening is one of the most important strategies for improving case detection.[3,4] Patients with TB should be screened for diabetes, while patients with diabetes who have TB symptoms or epidemiological risk factors should be screened for TB.[3,5] WHO guidance emphasizes that coordinated detection and management of both conditions should occur at the organizational and clinical levels.[3,4]

Integrated care is especially important because isolated TB treatment without glucose optimization may lead to poorer outcomes.[2,7,1,0] Similarly, diagnosing diabetes without considering TB can miss a serious underlying infection.[5,6] A combined approach reduces delay, improves communication between services, and supports earlier intervention.[3,4]

Diabetes management during TB treatment

Diabetes management during TB treatment should focus on achieving stable glycemic control while minimizing drug interactions and treatment toxicity.[1,5,7] Metformin is commonly preferred in many patients because it has no major interaction with rifampicin and may have additional beneficial effects, although renal and hepatic function should be monitored.[1,2,7] Insulin is often needed for severe hyperglycemia, especially when oral therapy is insufficient or when rapid control is required.[1,2,7]

Cardiovascular risk assessment is also important in TB-DM patients because diabetes adds long-term vascular risk even during acute infection.[1,7] Effective diabetes management should therefore include glucose monitoring, medication adjustment, nutrition counseling, and follow-up after TB treatment completion.[1,2,7]

Preventing diabetes in the TB patient

Prevention of diabetes in TB patients is best approached through lifestyle modification, nutritional support, and reduction of modifiable metabolic risk factors.[2,5] TB illness may worsen nutrition and physical inactivity, which can increase the risk of poor glucose control and future diabetes in vulnerable patients.[5,6]

Health services should use TB care as an opportunity for metabolic risk screening, education on diet and exercise, and referral for long-term prevention when needed.[1,2,8] Patients with TB, especially those with risk factors such as overweight, family history, or prior hyperglycemia, may benefit from follow-up glucose testing after completion of TB therapy.[1,2,8] This helps detect new-onset diabetes early and reduces the likelihood of missed chronic disease.[1,2,8]

Public health implications and strategies

TB-diabetes comorbidity is not only a clinical problem but also a public health issue.[3,5] The combined burden can increase transmission, worsen outcomes, and stretch already limited health system resources.[2,3,5,7] Public health strategies should therefore prioritize bidirectional screening, integrated care pathways, and surveillance systems that capture both diseases together.[2,3,7]

WHO guidance supports people-centred services that mainstream collaborative TB/DM activities within national guidelines and standard operating procedures.[5,7] Health systems should also strengthen referral networks so that patients diagnosed with one condition are promptly assessed for the other.[3,5] These strategies are especially important in high-burden settings where delayed diagnosis has a larger community impact.[3,5]

Policy and funding

Policy support is essential because sustainable TB-DM control requires coordinated financing, guideline development, and program integration.[3,5] WHO and related policy brief materials emphasize that primary health care platforms should integrate community-based diabetes screening alongside TB symptom screening.[3,5] Without policy backing, TB and diabetes programs tend to operate separately, which reduces efficiency and increases missed cases.[3,5,7]

Funding priorities should include staff training, screening tools, integrated data systems, and referral infrastructure.[5] Historically, estimates have shown that adding diabetes care to TB programs requires additional resources, but these investments may prevent worse downstream costs from treatment failure, relapse, and prolonged illness.[5] Countries should therefore treat TB-DM integration as a cost-effective public health investment rather than an optional add-on.[5,7]

Public awareness and education

Public awareness is crucial because both TB and diabetes can be under-recognized until disease is advanced.[2,5,6] Community education should explain that persistent cough, weight loss, and fever need prompt assessment, especially in people with diabetes or other risk factors.[5,2] Health messaging should also reinforce that good glucose control supports better TB outcomes and that TB can affect overall metabolic health.[1,2,7]

Education should target patients, families, community health workers, and front-line clinicians.[5,6] When people understand that TB and diabetes interact, they are more likely to seek care early, adhere to treatment, and return for screening after recovery.[2,5,6] This helps reduce stigma, delay, and preventable complications.[5,6]

Conclusion

Tuberculosis in the diabetic patient remains a true diagnostic dilemma because diabetes increases susceptibility, changes presentation, and may reduce diagnostic performance.[5,6] Early suspicion, appropriate microbiologic testing, bidirectional screening, and coordinated management of glycemia and TB are essential to improve outcomes.[3,4,7] In high-burden settings, integrated TB-diabetes care should be treated as a priority, not an optional addition.[3,5]

References

1. World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes. Geneva: WHO; 2011.

2. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152.

3. The WHO/Union Collaborative Framework for TB and Diabetes. The Union. 2011.

4. University of Queensland Library Guides. In-text citations - Vancouver (AMA) referencing

5. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.

6. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737-746.

7. Magee MJ, Salindri AD, Rustad SD, et al. Diabetes mellitus and tuberculosis. Clin Chest Med. 2019;40(4):887-901.

8. Lin Y, Harries AD, Kumar AMV, et al. Management of diabetes mellitus-tuberculosis. Int J Tuberc Lung Dis. 2017;21(4):479-487.

9. European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. 2011.

10. Wang C, Yu C, Shen H, et al. Tuberculosis and diabetes mellitus: evidence from the past decade and future perspectives. J Diabetes Res. 2020;2020:5137981.

11. Centers for Disease Control and Prevention. Tuberculosis and diabetes. Atlanta: CDC; 2024.

12. Niazi AK, Kalra S. Diabetes and tuberculosis: a review of the role of optimal glycemic control. J Diabetes Metab Disord. 2012;11:28.

13. European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: ECDC; 2011.

14. The Union. The WHO/Union Collaborative Framework for TB and Diabetes. 2011.

15. Foe-Essomba JR, Kenmoe S, et al. Diabetes mellitus and tuberculosis, a systematic review and meta-analysis with sensitivity analysis for studies comparable for confounders. PLoS One. 2021;16(12):e0261246.

16. Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis. 2007;45(4):428-435.

17. Ruslami R, Andriani A, Adi L, et al. Clinical management of combined tuberculosis and diabetes. PubMed. 2018.

18. Kumar A, et al. Screening for diabetes mellitus in tuberculosis patients: an evidence-based update. Indian J Med Res. 2022;156(1-2):17-25.

19. Tuberculosis and diabetes: current state and future perspectives. Wiley.

20. The Impact of Optimal Glycemic Control on Tuberculosis Treatment Outcomes. JMIR Public Health and Surveillance. 2024.

21. Effect of glycemic control and type of diabetes treatment on TB treatment outcomes. PubMed. 2025.

22. Diabetes among tuberculosis patients and its impact on tuberculosis treatment in South Asia: a systematic review and meta-analysis. PubMed. 2021.

23. Tuberculosis risk among people with diabetes mellitus in Sub-Saharan Africa: a systematic review. PubMed. 2022.

24. Tuberculosis treatment challenges in TB-diabetes comorbidities. PubMed. 2024.

25. Tuberculosis and diabetes mellitus: the complexity of a syndemic. PubMed. 2024.

26. Navigating the dual burden of diabetes mellitus and tuberculosis: a comprehensive review of clinical and public health strategies. PubMed. 2025.

27. Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies. Taylor & Francis. 2025.

28. Diabetes screening among people with tuberculosis. PMC. 2026.

29. Prevalence of diabetes among patients with tuberculosis in China. PubMed. 2021.

30. Tuberculosis (TB) treatment challenges in TB-diabetes comorbidities. PubMed. 2024.

31. WHO policy brief on integrating diabetes screening with TB symptom screening. WHO. 2022.

32. WHO TB-DM people-centred services guidance. WHO. 2023.